BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 9815535)

  • 41. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies.
    Goss PE; Reid CL; Bailey D; Dennis JW
    Clin Cancer Res; 1997 Jul; 3(7):1077-86. PubMed ID: 9815786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
    Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
    Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US; White DE; Rosenberg SA
    Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.
    Lazarus HM; Winton EF; Williams SF; Grinblatt D; Campion M; Cooper BW; Gunn H; Manfreda S; Isaacs RE
    Bone Marrow Transplant; 1995 Jun; 15(6):935-42. PubMed ID: 7581094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
    Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
    Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
    Alpaugh RK; Schultz J; McAleer C; Giantonio BJ; Persson R; Burnite M; Nielsen SE; Vitek L; Persson B; Weiner LM
    Clin Cancer Res; 1998 Aug; 4(8):1903-14. PubMed ID: 9717818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
    Schöffski P; Dumez H; Ruijter R; Miguel-Lillo B; Soto-Matos A; Alfaro V; Giaccone G
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1397-403. PubMed ID: 21465314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study of interleukin-2 in children with cancer.
    Roper M; Smith MA; Sondel PM; Gillespie A; Reaman GH; Hammond GD; Levitt D; Rosolen A; Colamonici OR; Neckers LM
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):305-11. PubMed ID: 1456395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
    Harman GS; Craig JB; Kuhn JG; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J; Tuttle RL; Lucas VS
    Cancer Res; 1988 Aug; 48(16):4706-10. PubMed ID: 3396016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
    Bailey H; Tutsch KD; Arzoomanian RZ; Tombes MB; Alberti D; Bruggink J; Wilding G
    Cancer Res; 1991 Feb; 51(4):1105-8. PubMed ID: 1705165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
    Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
    Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
    Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
    Trump DL; Tutsch KD; Koeller JM; Tormey DC
    Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects.
    Veltri S; Smith JW
    Stem Cells; 1996 Mar; 14(2):164-76. PubMed ID: 8991536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.